Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Median DFS Endpoint As Of May 24 Cutoff Date
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics announced preliminary disease-free survival (DFS) analysis from its Phase 1a study of ELI-002 7P. Patients receiving a 4.9mg dose of AMP-Peptide have not yet reached the median DFS endpoint as of the May 24 cutoff date.
June 27, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elicio Therapeutics' preliminary results from the Phase 1a study of ELI-002 7P are promising, with patients not yet reaching the median DFS endpoint at a 4.9mg dose. This could positively impact the stock price in the short term.
The preliminary results indicate that the treatment is effective, as patients have not yet reached the median DFS endpoint. This positive news is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100